Vapotherm (NYSE:VAPO) Lifted to Buy at Zacks Investment Research

Zacks Investment Research upgraded shares of Vapotherm (NYSE:VAPOGet Rating) from a hold rating to a buy rating in a report released on Wednesday, Zacks.com reports. The brokerage currently has $5.25 target price on the stock.

According to Zacks, “Vapotherm Inc. is a medical technology company. It designs and develops respiratory devices for the treatment of chronic lung and acute breathing disorders. The Company provides flow vapor transfer cartridges, delivery tubes and disinfection kits. Vapotherm Inc. is based in Exeter, New Hampshire. “

Several other research analysts also recently commented on VAPO. Canaccord Genuity Group reduced their price objective on Vapotherm from $21.00 to $12.00 in a research note on Wednesday, April 13th. BTIG Research dropped their target price on Vapotherm from $37.00 to $10.00 in a report on Monday, April 18th. Canaccord Genuity Group dropped their target price on Vapotherm from $21.00 to $12.00 and set a buy rating for the company in a report on Wednesday, April 13th. Finally, Piper Sandler cut Vapotherm from an overweight rating to an underweight rating and dropped their target price for the company from $23.00 to $8.00 in a report on Thursday, April 7th. One analyst has rated the stock with a sell rating and four have given a buy rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of Buy and an average price target of $8.85.

NYSE VAPO opened at $4.81 on Wednesday. The business has a fifty day moving average price of $10.94 and a 200 day moving average price of $16.55. Vapotherm has a one year low of $4.30 and a one year high of $31.87. The company has a debt-to-equity ratio of 0.60, a quick ratio of 1.70 and a current ratio of 2.54. The company has a market cap of $127.75 million, a P/E ratio of -2.09 and a beta of -0.38.

Vapotherm (NYSE:VAPOGet Rating) last posted its quarterly earnings data on Wednesday, May 4th. The company reported ($0.87) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.63) by ($0.24). Vapotherm had a negative net margin of 52.78% and a negative return on equity of 68.51%. The firm had revenue of $21.62 million during the quarter, compared to analyst estimates of $21.03 million. During the same period in the prior year, the company posted ($0.40) earnings per share. The firm’s revenue for the quarter was down 33.1% compared to the same quarter last year. As a group, sell-side analysts predict that Vapotherm will post -2.5 EPS for the current fiscal year.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Dark Forest Capital Management LP purchased a new position in shares of Vapotherm during the 3rd quarter worth $48,000. Barclays PLC grew its holdings in shares of Vapotherm by 92.8% during the 3rd quarter. Barclays PLC now owns 18,985 shares of the company’s stock worth $422,000 after purchasing an additional 9,137 shares during the period. Cubist Systematic Strategies LLC grew its holdings in shares of Vapotherm by 83.2% during the 3rd quarter. Cubist Systematic Strategies LLC now owns 23,309 shares of the company’s stock worth $519,000 after purchasing an additional 10,589 shares during the period. Goldman Sachs Group Inc. grew its holdings in shares of Vapotherm by 31.9% during the 3rd quarter. Goldman Sachs Group Inc. now owns 136,204 shares of the company’s stock worth $3,033,000 after purchasing an additional 32,936 shares during the period. Finally, Citigroup Inc. grew its holdings in shares of Vapotherm by 51.6% during the 3rd quarter. Citigroup Inc. now owns 28,141 shares of the company’s stock worth $627,000 after purchasing an additional 9,583 shares during the period. Institutional investors and hedge funds own 69.67% of the company’s stock.

Vapotherm Company Profile (Get Rating)

Vapotherm, Inc, a medical technology company, focuses on the development and commercialization of proprietary high velocity therapy products used to treat patients of various ages suffering from respiratory distress in the United States and internationally. The company offers precision flow systems, such as Precision Flow Hi-VNI, Precision Flow Plus, Precision Flow Classic, and Precision Flow Heliox that deliver heated, humidified, and oxygenated air at a high velocity to patients through a small-bore nasal interface.

Read More

Get a free copy of the Zacks research report on Vapotherm (VAPO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Vapotherm Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vapotherm and related companies with MarketBeat.com's FREE daily email newsletter.